Study on the expression of IgG in prostate cancer and its effect on prostate cancer

Abstract

Abstract Prostate cancer (PC) is the second leading cause of cancer-related death in men. Recent studies have discovered immunoglobulin G (IgG) in the progression and pathogenesis of various cancers. This study aimed to explore the role of IgG in PC. By immunohistochemistry, IgG was found to be highly expressed in PC tissues. In addition, we assessed whether intervention with the PI3K-Akt pathway inhibitor pimasertib can improve the immune function of patients. IgG-FCGR1A small interfering RNA (siRNA) was used to silence IgG expression in PC3 and C4-2 cells. The efficiency of IgG knockdown was confirmed using Western blotting. The effects of Akt pathway inhibitors on the apoptosis of PC-3 and C4-2 prostate cancer cells and on the SOX2/HIF-1α pathway were also assessed by RT-PCR. PC3 cells transfected with or without IgG-FCGR1A short hairpin RNA (shRNA) were injected subcutaneously into the flanks of 6-week-old male nude mice to establish a xenograft mouse model. The elimination of IgG significantly inhibited the proliferation of PC3 and C4-2 cells and the expression of IgG protein in vitro. Similarly, in vivo studies showed that IgG knockout significantly reduced tumour volume of nude mice. IgG plays an important role in the growth of PC and may be a target for PC treatment, providing information for clinical research on PC.